Get started
Author

Kun-Ming Rau

Observed names: K.-M. Rau, K.M. Rau, Kung-Ming Rau, Kung‐Ming Rau
Observed institutions: The University of Texas MD Anderson Cancer Center, Chang Gung University, Chang Gung Memorial Hospital, E-Da Hospital, Kaohsiung Chang Gung Memorial Hospital, Yuan's General Hospital, I-Shou University
ORCID: 0000-0002-1209-3043
Observed ORCID: 0000-0002-1209-3043
OpenAlex ID: A5101690034
Cancer-specific activation of the survivin promoter and its potential use in gene therapy
2004 · Jin-Shing Chen, Jaw-Ching Liu, et al. · Cancer Gene Therapy · 115
Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis
2020 · Pi-Ling Chou, Ya-Ping Huang, et al. · International Journal of Nanomedicine · 48
PDF
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
2024 · Ying-Chun Shen, Tsung-Hao Liu, et al. · Journal of Clinical Oncology · 38
Impact of Combined Hospice Care on Terminal Cancer Patients
2011 · Song-Seng Loke, Kung-Ming Rau, et al. · Journal of Palliative Medicine · 37
Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response
2020 · Kun-Ming Rau, Chien-Ting Liu, et al. · Journal of Clinical Medicine · 31
PDF
Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer
2024 · Wen-Chi Shen, Shin-Cheh Chen, et al. · Scientific Reports · 27
PDF
Increased cumulative doses and appearance of hand‐foot skin reaction prolonged progression free survival in sorafenib‐treated advanced hepatocellular carcinoma patients
2018 · Wen‐Tsan Chang, Sheng‐Nan Lu, et al. · The Kaohsiung Journal of Medical Sciences · 15
PDF
Weekly Paclitaxel Combining with Gemcitabine is an Effective and Safe Treatment for Advanced Breast Cancer Patients
2010 · K.-M. Rau, S.-H. Li, et al. · Japanese Journal of Clinical Oncology · 10
An evaluation of focal adhesion kinase in breast cancer by tissue microarrays.
2013 · Shyr-Ming Sheen-Chen, Chun-Ying Huang, et al. · PubMed · 9
Differences Between Inpatient Hospice Care and In-hospital Nonhospice Care for Cancer Patients
2011 · Song-Seng Loke, Kung-Ming Rau · Cancer Nursing · 8
Luteolin (LUT) Induces Apoptosis and Regulates Mitochondrial Membrane Potential to Inhibit Cell Growth in Human Cervical Epidermoid Carcinoma Cells (Ca Ski)
2024 · Sung-Nan Pei, Kuan-Ting Lee, et al. · Biomedicines · 7
PDF
A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study
2021 · Sung-Nan Pei, Chun-Kai Liao, et al. · Cancers · 5
PDF
S-1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection—A Propensity Score Matching Analysis
2020 · Meng-Che Hsieh, Shih-Ho Wang, et al. · Cancers · 5
PDF
A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients
2018 · Hung-Chih Hsu, Wen-Chi Chou, et al. · Cancer Management and Research · 5
PDF
High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy
2017 · Kun-Ming Rau, Yu-Li Su, et al. · Molecular Medicine Reports · 4
PDF
Effects of Hydrogen Water Gargling on Oral Mucositis and Pain in Head and Neck Cancer Patients: A Randomized Controlled Pilot Study
2026 · Hui-Ting Tsai, Chih-Jen Huang, et al. · Integrative Cancer Therapies · 2
Repurposing a Lipid-Lowering Agent to Inhibit TNBC Growth Through Cell Cycle Arrest
2025 · Yi-Chiang Hsu, Kuan-Ting Lee, et al. · Current Issues in Molecular Biology · 2
PDF
An evaluation of fatty acid-CoA ligase 4 in breast cancer.
2014 · Chin-Hua Tsai, Shyr-Ming Sheen-Chen, et al. · PubMed · 2
Glypican-3 Expression in Breast Cancer
2015 · Ching-Hua Tsai, Wei-Ti Su, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 1
2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies
2015 · W.W. Ma, I. Chung, et al. · European Journal of Cancer · 1
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management
2026 · Jiun-I Lai, Chih-Chiang Hung, et al. · Journal of Breast Cancer
Abstract P1-12-03: Clinical Efficacy and Outcomes of Astragalus Polysaccharides (PG2) toward Cancer-related Fatigue of Advanced Breast Cancer Patients
2025 · Ming-Shen Dai, Chih-Chiang Hung, et al. · Clinical Cancer Research
Prognostic impact of codon-specific KRAS mutational status on survival in patients with metastatic colorectal cancer treated with TAS-102 or regorafenib.
2024 · Meng-Che Hsieh, Kun-Ming Rau, et al. · Journal of Clinical Oncology
PDF
221PD Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
2016 · L.-T. Chen, C.-P. Li, et al. · Annals of Oncology
PDF
Trimodality Treatment of Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma: A Single Institute Experience in Southern Taiwan
2012 · Y.-H. Chen, H.-I Lu, et al. · Annals of Oncology
PDF
Works count: 27
Citation count: 372
H-index: 9
I10-index: 8
Year
Topic
Type